The Tumor Microenvironment of Primitive and Metastatic Breast Cancer: Implications for Novel Therapeutic StrategiesGiovanni Zarrilli, Matteo Fassan, Gianluca Businello et al.|International Journal of Molecular Sciences|2020Cited by 36
A Prognostic Model Based on Residual Cancer Burden and Tumor-Infiltrating Lymphocytes on Residual Disease after Neoadjuvant Therapy in HER2+ Breast CancerFederica Miglietta, Maria Vittoria Dieci, Moira Ragazzi et al.|Clinical Cancer Research|2023Cited by 13
Incorporating weekly carboplatin in anthracycline and paclitaxel-containing neoadjuvant chemotherapy for triple-negative breast cancer: propensity-score matching analysis and TIL evaluationMaria Vittoria Dieci, Valentina Guarneri, Luisa Carbognin et al.|British Journal of Cancer|2022Cited by 9
PI3K/PTEN/mTOR pathway dynamic tracking and prognostic value in HR+/HER2− BC patients with residual disease after neoadjuvant chemotherapy: a cohort studyFederica Miglietta, Matteo Fassan, Valentina Carraro et al.|Journal of Clinical Pathology|2023Cited by 2
Gene expression profiling of paired primary breast cancers and brain metastases to identify brain metastases-specific biological changes.Gaia Griguolo, Valentina Guarneri, Maria Vittoria Dieci et al.|Journal of Clinical Oncology|2023Cited by 0